Dementia: The R&D Landscape
Marsden, G. and Mestre-Ferrandiz, J.

Sign Up for the OHE News Bulletin
Why not sign up for our news bulletin? Around once a week we will send you a round-up of the latest news, events and publications from OHE.
This OHE Research Paper provides an overview of the current dementia R&D landscape. The research was undertaken by OHE for Imperial College and the UK Department of Health.
The research is intended to provide a factual report of the current R&D landscape. A discussion of the reasons behind, and the implications of, the difficulties that are highlighted in this report will be published elsewhere*.
The report begins with a brief overview of the current thinking on the reasons for successes and failures of dementia treatments, based on a selective literature review. Key observations include:
- R&D costs are higher for neurology and Alzheimer’s disease (AD) (as well as respiratory and oncology) than other therapy areas
- Higher costs are likely due to lower success rates and longer development times
- Recruitment of trial participants is a key challenge in the area of dementia.